AtriCure (ATRC) Misses Q1 EPS by 3c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG
May 2, 2024 5:25 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $58.00 (from $65.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q1 revenue of $108.9M (+16.4% y/y rep, +16.3% y/y cc), above consensus of $106.9M. U.S. Q1 revenue was $90.2M (+15.4% y/y), slightly higher than consensus of $89.5M, and International revenue of $18.6M (+21.5% y/y rep, +21.1% y/y cc) beat consensus of $17.4M. The closely watched U.S. Appendage Management segment reported $35.9M (+11% y/y) in Q1 sales, missing consensus... More
